The purpose of the study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III guidelines, overall and by country, in the following sub-populations: * Primary/secondary prevention patients. * Patients with metabolic syndrome (according to NCEP III definition). In addition, the purpose is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines/national guidelines, in the survey population and in the following sub-populations: * Primary/secondary prevention patients. * Patients with metabolic syndrome.
Study Type
OBSERVATIONAL
Enrollment
4,053
Research Site
Riyadh, Central, Saudi Arabia
Research Site
Dammam, Eastern Province, Saudi Arabia
Research Site
Aljouf, North, Saudi Arabia
Research Site
Jeddah, Western, Saudi Arabia
Research Site
Makah, Western, Saudi Arabia
To establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III / updated 2004 NCEP ATP III guidelines, overall and by country.
Time frame: 6 months- One visit only, no follow up visits.
The proportion of patients reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III in the following sub-populations - Primary/secondary prevention patients - Patients with metabolic syndrome (according to NCEP III definition).
Time frame: 6 months - One visit only, no follow up visits.
The proportion of patients reaching the LDL-C goals according to the Third Joint European Task Force guidelines / national guidelines, in the following sub-populations:-Primary/secondary prevention patients -Patients with metabolic syndrome.
Time frame: 6 months- One visit only, no follow up visits.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.